Document
IPR2023-00724, No. 2509 Exhibit - EX2509 Novo Nordisk, Financial report for the period 1 January 2021 to 31 December 2021 Feb 2, 2022 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2509 Exhibit - EX2509 Novo Nordisk, Financial report for the period 1 January 2021 to 31 December 2021 Feb 2, 2022 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2404 Exhibit - EX2404 US Food Drug Administration, DrugsFDA, Onglyza® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2404 Exhibit - EX2404 US Food Drug Administration, DrugsFDA, Onglyza® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2469 Exhibit - EX2469 US Food Drug Administration, DrugsFDA, Stegluromet (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2469 Exhibit - EX2469 US Food Drug Administration, DrugsFDA, Stegluromet (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2015 Exhibit - EX2015 Shaman, A, et al, “Effect of the Glucagon Like Peptide 1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2...
Cite Document
IPR2023-00724, No. 2015 Exhibit - EX2015 Shaman, A, et al, “Effect of the Glucagon Like Peptide 1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes Po
+ More Snippets
Document
IPR2023-00724, No. 2519 Exhibit - EX2519 Gorgojo Martínez, JJ, et al, Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp 1 Receptor Agonists...
Cite Document
IPR2023-00724, No. 2519 Exhibit - EX2519 Gorgojo Martínez, JJ, et al, Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp 1 Receptor Agonists A Multidisci
+ More Snippets
Document
IPR2023-00724, No. 2374 Exhibit - EX2374 Tran, KL, et al, Overview of Glucagon Like Peptide 1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes, Am Health Drug Benefits...
Cite Document
IPR2023-00724, No. 2374 Exhibit - EX2374 Tran, KL, et al, Overview of Glucagon Like Peptide 1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes, Am Health Drug Benefits 2017 Jun 1
+ More Snippets
Document
IPR2023-00724, No. 2447 Exhibit - EX2447 US Food Drug Administration, DrugsFDA, Trulicity® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2447 Exhibit - EX2447 US Food Drug Administration, DrugsFDA, Trulicity® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2101 Exhibit - EX2101 Marso, SP, et al, Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, 3751834 1844 2016 (P.T.A.B. Jan. 17, ...
Cite Document
IPR2023-00724, No. 2101 Exhibit - EX2101 Marso, SP, et al, Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, 3751834 1844 2016 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2497 Exhibit - EX2497 Novo Nordisk, Financial report for the period 1 January 2018 to 31 December 2018 Feb 1, 2019 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2497 Exhibit - EX2497 Novo Nordisk, Financial report for the period 1 January 2018 to 31 December 2018 Feb 1, 2019 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2445 Exhibit - EX2445 Trulicity® Prescribing Information rev Aug 2017 (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2445 Exhibit - EX2445 Trulicity® Prescribing Information rev Aug 2017 (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2365 Exhibit - EX2365 US Food Drug Administration, DrugsFDA, Amaryl® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2365 Exhibit - EX2365 US Food Drug Administration, DrugsFDA, Amaryl® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2443 Exhibit - EX2443 US Food Drug Administration, DrugsFDA, Invokamet® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2443 Exhibit - EX2443 US Food Drug Administration, DrugsFDA, Invokamet® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2053 Exhibit - EX2053 Declaration of Smita Agarwal (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2053 Exhibit - EX2053 Declaration of Smita Agarwal (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2427 Exhibit - EX2427 US Food Drug Administration, DrugsFDA, Nesina® (P.T.A.B. Jan. 17, 2024)
Cite Document
IPR2023-00724, No. 2427 Exhibit - EX2427 US Food Drug Administration, DrugsFDA, Nesina® (P.T.A.B. Jan. 17, 2024)
+ More Snippets
Document
IPR2023-00724, No. 2105 Exhibit - EX2105 Nauck, MA, et al, Cardiovascular Actions and Clinical Outcomes With Glucagon Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibito...
Cite Document
IPR2023-00724, No. 2105 Exhibit - EX2105 Nauck, MA, et al, Cardiovascular Actions and Clinical Outcomes With Glucagon Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors, Circulat
+ More Snippets